![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1321047
¾à¹°À¯ÀüüÇÐ ½ÃÀå : ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø(2017-2027³â)Pharmacogenomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Technology, By Service, By Application, By End User, By Region |
¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ½ÃÀåÀº ¿¹Ãø ±â°£ Áß °ß°íÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±× ¹è°æ¿¡´Â ÇコÄÉ¾î ºÐ¾ß¿¡¼ °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ º¸±Þ°ú äÅÃÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¾à¹°À¯ÀüüÇÐÀº ȯÀÚÀÇ DNA°¡ ¾à¹°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ¿¬±¸ÇÕ´Ï´Ù. ¾Ï, ½ÉÇ÷°ü Áúȯ, È£Èí±â Áúȯ, ½ÅÀå Áúȯ µî ´Ù¾çÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ÁúȯÀÇ Ä¡·á¸¦ À§ÇÑ ¸ÂÃã Ä¡·áÁ¦ÀÇ °³¹ß ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ¿© ¼¼°è ¾à¹°À¯ÀüüÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ÁøÃâÇÏ´Â ´Ù¾çÇÑ ±â¾÷°ú ÇÔ²² R&D Ȱµ¿ÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¼¼°è ¾à¹°À¯ÀüüÇÐ ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 6¿ù Infosys Limited´Â Á¦¾à »ê¾÷ÀÇ ÇÁ·Î¼¼½º¸¦ µðÁöÅÐÈÇÏ°í ´õ °·ÂÇÑ ºñÁî´Ï½º ¼º°ú¸¦ ÃËÁøÇϱâ À§ÇØ °³ÀÎÈµÈ ÀÇ·á ¼Ö·ç¼ÇÀ» ¹ßÇ¥Çß½À´Ï´Ù.
ºÎÀÛ¿ë(ADR)Àº ÀÓ»ó »ç¿ë Áß¿¡ ³ªÅ¸³ª´Â ¾à¹° °ü·Ã ºÎÀÛ¿ëÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¶ÇÇÑ ºÎÀÛ¿ëÀº Àå±â°£ Áö¼ÓµÉ ¼ö ÀÖ°í ȯÀÚÀÇ »îÀÇ ÁúÀ» ÀúÇϽÃ۸ç, ½É°¢ÇÑ »óȲ¿¡¼´Â ÀÌȯÀ²°ú »ç¸Á·üÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ Ãâ½ÃµÇ´Â ¾à¹°ÀÇ ¼ö°¡ Áõ°¡Çϰí, ƯÈ÷ °í·ÉÃþ µî ´Ù¾çÇÑ Áúº´À» Ä¡·áÇϱâ À§ÇÑ Æú¸®ÆÄ¸¶½Ã½ºÀÇ ±Þ¼ÓÇÑ Áõ°¡´Â ¸ðµÎ ADRÀÇ ¼¼°èÀû ¹ß»ý¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ADR »ç·ÊÀÇ ±Þ¼ÓÇÑ Áõ°¡´Â º¸´Ù È¿°úÀûÀÎ Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿Í ¾à¹°À¯ÀüüÇÐÀº ADRÀÇ °¡´É¼ºÀ» °¨¼Ò/Á¦°ÅÇÏ¸é¼ ÁÁÀº Ä¡·á È¿°ú¸¦ ³¾ ¼ö Àִ ƯÁ¤ Ä¡·á ¸ðµâÀ» ÇÊ¿ä·Î Çϴ ȯÀÚ¸¦ ½Äº°ÇÔÀ¸·Î½á ÀÌ ¹®Á¦¿¡ ´ëÇÑ ½ÇÇö °¡´ÉÇÑ ÇØ´äÀ» Á¦½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áß¿äÇÑ ¹®Á¦µéÀ» ÇØ°áÇÏ·Á´Â ½Ãµµ°¡ È®¸³µÊ¿¡ µû¶ó ¼¼°è ¾à¹°À¯ÀüüÇÐ ½ÃÀåÀÇ ¼ºÀåÀº ÇâÈÄ ¼ö³â°£ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯ÀüÀû üÁú°ú ȯ°æ ¹× ÁÖº¯ ȯ°æÀÌ »ç¶÷ÀÇ °Ç°¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» °í·ÁÇÑ Ä¡·á¹ý°ú ÀǾàǰÀ» °³¹ßÇϱâ À§ÇÑ R&D Ȱµ¿ Áõ°¡´Â 2027³â±îÁö ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤¹ÐÀÇ·á ¶Ç´Â ¸ÂÃãÀÇ·á´Â ¾à¹°À¯ÀüüÇÐÀÇ ±Ù°£À» ÀÌ·ç°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤Åðú ¼ö¿ä Áõ°¡´Â ¼¼°è ¾à¹°À¯ÀüüÇÐÀÇ ¼ºÀåÀ» ´õ¿í Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¼¼°è »ý¸í°øÇÐ ¹× Á¦¾à ±â¾÷, ÇÐ°è ¹× ¿¬±¸ ±â°üÀº ¾à¹°À¯ÀüüÇÐ °ü·Ã ÅõÀÚ, R&D ÀÚ±Ý ¹× ±âŸ Ȱµ¿ Áõ°¡, ÀÓ»ó½ÃÇè ½Ç½Ã µîÀ» ÅëÇØ ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ±¹¸³º¸°Ç¿øÀÌ 2022³â 5¿ù ¹ßÇ¥ÇÑ º¸°í¼¿¡ µû¸£¸é ¾Ï À¯Àüü °ü·Ã R&D Ȱµ¿¿¡ ´ëÇÑ ÁöÃâÀº 2016³â 8¾ï 6,100¸¸ ´Þ·¯¿¡¼ 2022³â 12¾ï 2,000¸¸ ´Þ·¯·Î Áõ°¡Çß½À´Ï´Ù. ¸¶Âù°¡Áö·Î ¼¼°è ±âŸ Áö¿ª¿¡¼µµ °³ÀÎ ¸ÂÃãÇü ÀÇ·á °ü·Ã R&D Ȱµ¿ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 10¿ù À̽º¶ó¿¤ Á¤¹ÐÀÇ·á ÆÄÆ®³Ê½Ê(IPMP)Àº ¾Ï, Å©·Ðº´, Èñ±ÍÁúȯÀ» Æ÷ÇÔÇÑ ¸ÂÃãÇü ÀÇ·á ¿¬±¸¸¦ À§ÇØ À̽º¶ó¿¤ÀÇ 11°³ ÇÁ·ÎÁ§Æ®¿¡ ¾à 990¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» Áö¿øÇß½À´Ï´Ù.
¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ½ÃÀåÀº ±â¼ú, ¼ºñ½º, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ±¸ºÐÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼úº°·Î PCR, ½ÃÄö½Ì, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, °Ö Àü±â¿µµ¿, Áú·® ºÐ¼® ¹× ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¼ºñ½º¸¦ ±â¹ÝÀ¸·Î ½ÃÀåÀº À¯ÀüÀÚÇü ºÐ¼®, SNP ½Äº°, ¾à¸®À¯ÀüÇÐÀû °Ë»ç, ±âŸ·Î ¼¼ºÐȵ˴ϴÙ. ¾ÖÇø®ÄÉÀ̼ÇÀ» ±âÁØÀ¸·Î ½ÃÀåÀº ½Å¾à °³¹ß, Á¾¾çÇÐ, ½Å°æ ¹× Á¤½ÅÀÇÇÐ, ÅëÁõ °ü¸®, ½ÉÇ÷°ü Áúȯ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó º´¿ø, »ý¸í°øÇÐ ¹× Á¦¾àȸ»ç, ±âŸ·Î ºÐ·ùµË´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ³²¹Ì¿¡¼ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº Ȱ¹ßÇÑ R&D Ȱµ¿À¸·Î ÀÎÇØ ¼¼°è ±¹°¡ Áß ¾à¹°À¯ÀüüÇÐ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, 2022³â ¹Ì±¹ÀÇ °úÇÐ R&D ¸ÅÃâÀº 81¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Abbott Laboratories, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., AstraZeneca Plc., F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Eurofins Scientific SE, Pacific Biosciences of California Inc, Qiagen N.V., PerkinElmer, Inc., Oxford Nanopore Technologies Limited, Agilent Technologies, Inc., Myriad Genetics, Inc., Admera Health, LLC´Â ¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ ÀϺÎÀÔ´Ï´Ù.
TechSci Research´Â ÁÖ¾îÁø ½ÃÀå µ¥ÀÌÅ͸¦ »ç¿ëÇÏ¿© ±â¾÷ÀÇ °íÀ¯ÇÑ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÈÇÒ ¼ö ÀÖ´Â ¼ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. º¸°í¼´Â ´ÙÀ½°ú °°Àº Ä¿½ºÅ͸¶ÀÌÁ¦À̼ÇÀÌ °¡´ÉÇÕ´Ï´Ù.
The global pharmacogenomics market is expected to grow at a robust rate during the forecast period. This can be ascribed to the growing popularity and adoption of personalized medicine in the field of healthcare. Pharmacogenomics studies the way a patient's DNA affects the way his/her body responds to drugs. The growing prevalence of various chronic diseases such as cancer, cardiovascular diseases, respiratory ailments, and renal disorders, among others, has significantly increased the demand for developing personalized treatments for the treatment of these diseases, thereby driving the growth of global pharmacogenomics market. Additionally, increasing research & development activities along with various companies entering the personalized medicine space is expected to create lucrative opportunities for the growth of global pharmacogenomics market. For instance, in June 2020, Infosys Limited launched personalized medicine solutions for the pharmaceutical industry to digitally transform their processes and drive stronger business outcomes.
Adverse Drug Reactions (ADRs) include medication-related side effects that develop during clinical use. Furthermore, they can continue for a long time, decreasing a patient's quality of life. ADRs can cause morbidity and fatality in severe circumstances. The increasing number of medications on the market and the rapid rise of polypharmacy to treat different disorders, especially in the elderly population, among others, are all contributing to the global occurrence of ADRs. The fast growth in the number of ADR cases is driving the demand for more effective treatment regimens. Precision medicine and pharmacogenomics offer a feasible answer to this problem by identifying patients who require specific therapeutic modules that will give good therapy while reducing/eliminating the possibility of any ADR. With established attempts to address such important problems, the global pharmacogenomics market growth is expected to witness significant growth in the coming years.
The growing research & development activities for developing treatments and drugs, taking into consideration the genetic makeup and effect of environment and surroundings on human health, are expected to create lucrative opportunities for market growth through 2027. Precision medicine or personalized medicine forms the basis of pharmacogenomics; the growing adoption and demand for personalized medicine are further expected to support the growth of global pharmacogenomics. Additionally, biotechnology & pharmaceutical companies and academic & research institutions worldwide are making investments, increasing their research & development funds and related activities, and conducting clinical trials, among others related to pharmacogenomics, thereby creating opportunities for market growth in the coming years. For instance, according to a report published by the National Institute of Health of the United States in May 2022, the expenditure on research & development activities related to cancer genomics increased from USD861 million in 2016 to USD1,220 million in 2022. Similarly, the research and development activities related to personalized medicines are increasing across other parts of the globe also. For instance, in October 2021, the Israel Precision Medicine Partnership (IPMP) awarded funding of about USD 9.9 million to 11 projects in Israel for the research of personalized medicine that includes cancers, Crohn's disease, and rare diseases.
The global pharmacogenomics market can be segmented by technology, service, application, end-user, by region. Based on technology, the market can be categorized into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. Based on service, the market can be fragmented into genotyping, SNP identification, pharmacogenetic testing, and others. Based on application, the market can be grouped into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others. Based on end-user, the market can be classified into hospitals & clinics, biotechnology & pharmaceutical companies, and others. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa, and South America. The United States dominated the pharmacogenomics market among all the countries globally on account of increasing research and development activities in the country. In 2022, the revenue in scientific research & development is projected to reach USD8.11 billion in the United States.
Abbott Laboratories, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., AstraZeneca Plc., F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Eurofins Scientific SE, Pacific Biosciences of California Inc., Qiagen N.V., PerkinElmer, Inc., Oxford Nanopore Technologies Limited, Agilent Technologies, Inc., Myriad Genetics, Inc, Admera Health, LLC are some of the leading players operating in the global pharmacogenomics market.
In this report, global pharmacogenomics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in global pharmacogenomics market.
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: